Delivery Order SPE2DB22D2007-SPE2DB25FJ1KD

Award Date 5/9/25
Potential Completion Date 5/12/25
Potential Value $20K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $4,389.92, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, and has an ultimate completion date of January 9, 2025. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract, valued at $4,474.74, is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. This award is a delivery order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999 and running through November 2026. The IDC serves as a...
This federal contract award, valued at $10,519.68, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, and has an ultimate completion date of January 15, 2025. The contract is a Delivery Order under an Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA Troop Support Medical, valued at...
This federal contract award, valued at $8,480.96, was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a completion date of November 18, 2024. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, valued...
This federal contract award, valued at $33,135.19, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a pharmaceutical product, with a completion date of January 9, 2025. The contract is a Delivery Order under a broader Indefinite Delivery Contract (IDC) between Amerisourcebergen and the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $26,727.50 firm fixed price delivery order is for the supply of GARDASIL 9 syringes, a vaccine product. The contract is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This IDC serves as a primary vehicle for providing a...
This federal contract award, valued at $35,018.20, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the delivery of GARDASIL 9 syringes, a vaccine product, with a completion date of January 23, 2024. This award is a delivery order under a broader Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999 and running...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major supplier of pharmaceutical products and medical supplies to the U.S. government. The contract, valued at $29,771.62, is for the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a performance period ending on June 21, 2024. The award is a Delivery Order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical,...
This federal contract award, valued at $13,784.70, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award covers the delivery of GARDASIL 9 SYRINGE 0.5ML, a vaccine product, with a completion date of December 16, 2024. The contract is structured as a Delivery Order under an Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, valued at $999,999,999...
This federal contract award, valued at $6,167.15, was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The award is a delivery order contract for the provision of GARDASIL 9 SYRINGE 0.5ML, a vaccine product. The contract has an ultimate completion date of November 20, 2024 and is a firm fixed-price arrangement. This award is part of a larger Indefinite Delivery Contract (IDC) between...
  • SPE2DB22D2007
    Indefinite Delivery Contract
  • SPE2DB22D2007-SPE2DB25FJ1KD
    Delivery Order

This federal contract award, valued at $20,378.99, was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The award is a delivery order under an Indefinite Delivery Contract (IDC) valued at $999,999,999.00, which provides a comprehensive global pharmaceutical support vehicle to the DLA Troop Support Medical through December 2026. This delivery order is for the supply of 4,568,201,435 units of the GARDASIL 9 SYRINGE 0.5ML vaccine, with a completion date of May 12, 2025. The contract is a firm fixed-price arrangement and does not have a set-aside designation, indicating open competition. As a critical vendor supporting federal medical procurement needs, particularly for military and veteran healthcare systems, Amerisourcebergen Drug Corp is well-positioned to fulfill this order as part of its larger IDC with the DLA.

Generated 8/8/25, 10:03 AM